Работа выполнена без спонсорской поддержки.1.Клинические рекомендации Министерства здравоохранения РФ по диагностике и лечению неалкогольной жировой болезни печени. Москва, 2024. [Clinical guidelines of the Russian Ministry of Health for the diagnosis and treatment of non-alcoholic fatty liver disease. Moscow, 2024. (In Russ.)]. URL: https://cr.minzdrav.gov.ru/view-cr/748_2?ysclid=mh3mc0rmzb7743525322.Ивашкин В.Т., Маевская М.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104-140. [Ivashkin V.T., Maevskaya M.V., Zharkova M.S., et al. [Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russ J Gastroenterol Hepatol Coloproctology. 2022;32(4):104-140. (In Russ.)]. https://dx.doi.org/10.22416/1382-4376-2022-32-4-104-1403.Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Распространённость неалкогольной жировой болезни печени в России: метаанализ. Consilium Medicum. 2023;25(5):313-319. [Maev I.V., Andreev D.N., Kucheryavyy Yu.A. Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis. Consilium Medicum. 2023;25(5):313-319. (In Russ.)]. https://dx.doi.org/10.26442/20751753.2023.5.2021554.Byrne C.D., Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1):S47-S64. https://dx.doi.org/10.1016/j.jhep.2014.12.0125.Xian Y.X., Weng J.P, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2021;134(1):8-19. https://dx.doi.org/10.1097/CM9.00000000000012636.Muthiah M.D., Cheng Han N., Sanyal A.J. A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications – What the non‐specialist needs to know. Diabetes Obes Metab. 2022;24(S2):3-14. https://dx.doi.org/10.1111/dom.145217.Obika M., Noguchi H. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease. Exp Diabetes Res. 2012;2012:1-12. https://dx.doi.org/10.1155/2012/1457548.Rinella M.E., Lazarus J.V., Ratziu V., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. https://dx.doi.org/10.1097/HEP.00000000000005209.Targher G., Day C.P., Bonora E. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2010;363(14):1341-1350. https://dx.doi.org/10.1056/NEJMra091206310.Northup P., Argo C., Shah N., Caldwell S. Hypercoagulation and Thrombophilia in Nonalcoholic Fatty Liver Disease: Mechanisms, Human Evidence, Therapeutic Implications, and Preventive Implications. Semin Liver Dis. 2012;32(01):039-048. https://dx.doi.org/10.1055/s-0032-130642511.Ciardullo S., Ballabeni C., Trevisan R., Perseghin G. Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules. 2022;12(1):105. https://dx.doi.org/10.3390/biom1201010512.Xiao G., Zhu S., Xiao X., Yan L., Yang J., Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis. Hepatology. 2017;66(5):1486-1501. https://dx.doi.org/10.1002/hep.2930213.Petzold G. Role of Ultrasound Methods for the Assessment of NAFLD. J Clin Med. 2022;11(15):4581. https://dx.doi.org/10.3390/jcm1115458114.Berzigotti A., Tsochatzis E., Boursier J., et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021;75(3):659-689. https://dx.doi.org/10.1016/j.jhep.2021.05.02515.Pu K., Wang Y., Bai S., et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):51. doi:10.1186/s12876-019-0961-916.Lin H., Lee H.W., Yip T.C.F., et al. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease. JAMA. 2024;331(15):1287. https://dx.doi.org/10.1001/jama.2024.144717.Gu J., Liu S., Du S., et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol. 2019;29(7):3564-3573. https://dx.doi.org/10.1007/s00330-019-06072-418.De Franchis R., Bosch J., Garcia-Tsao G., et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-974. https://dx.doi.org/10.1016/j.jhep.2021.12.02219.Verhaegh P., Bavalia R., Winkens B., et al. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):837-861. https://dx.doi.org/10.1016/j.cgh.2017.08.02420.Kleiner D., Brunt E. Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research. Semin Liver Dis. 2012;32(01):003-013. https://dx.doi.org/10.1055/s-0032-130642121.Bedossa P. Current histological classification of NAFLD: strength and limitations. Hepatol Int. 2013;7(S2):765-770. https://dx.doi.org/10.1007/s12072-013-9446-z22.Tacke F., Horn P., Wai-Sun Wong V., et al. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. https://dx.doi.org/10.1016/j.jhep.2024.04.03123.Zelber‐Sagi S., Salomone F., Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non‐alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017;37(7):936-949. https://dx.doi.org/10.1111/liv.1343524.Lee D., Chiavaroli L., Ayoub-Charette S., et al. Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials. Nutrients. 2022;14(14):2846. https://dx.doi.org/10.3390/nu1414284625.Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol. 2012;57(1):157-166. https://dx.doi.org/10.1016/j.jhep.2012.02.02326.Nadinskaia M., Maevskaya M., Ivashkin V., et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959-975. https://dx.doi.org/10.3748/wjg.v27.i10.95927.Byrnes K., Blessinger S., Bailey N.T., Scaife R., Liu G., Khambu B. Therapeutic regulation of autophagy in hepatic metabolism. Acta Pharm Sin B. 2022;12(1):33-49. https://dx.doi.org/10.1016/j.apsb.2021.07.02128.Karedath J., Javed H., Ahsan Talpur F., et al. Effect of Vitamin E on Clinical Outcomes in Patients With Non-alcoholic Fatty Liver Disease: A Meta-Analysis. Cureus. Published online December 21, 2022. https://dx.doi.org/10.7759/cureus.3276429.Vivarelli F., Canistro D., Cirillo S., et al. Co-carcinogenic effects of vitamin E in prostate. Sci Rep. 2019;9(1):11636. https://dx.doi.org/0.1038/s41598-019-48213-130.Райхельсон К.Л., Кондрашина Э.А. Адеметионин в лечении повышенной утомляемости/слабости при заболеваниях печени: систематический обзор. Терапевтический архив. 2019;91(2):134–142. [Raikhelson K.L., Kondrashina E.A. Ademethionine in the treatment of fatigue in liver diseases: a systematic review. Ter Arkh. 2019;91(2):134-142. https://dx.doi.org/10.26442/00403660.2019.02.00013031.Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020;12(2):46-63. https://dx.doi.org/10.4254/wjh.v12.i2.4632.Маевская М.В., Луньков В.Д., Гейвандова Н.И. и др. Бициклол в лечении пациентов с хроническими диффузными заболеваниями печени. Медицинский совет. 2020;(15):78-89 [Maevskaya M.V., Lunkov V.D., Geyvandova N.I., et al. Bicyclol in the treatment of patients with chronic diffuse liver diseases. Meditsinskiy Sovet = Medical Councilium. 2020;(15):78-89. (In Russ.)]. https://dx.doi.org/10.21518/2079-701X-2020-15-78-8933.Butterworth R.F., Kircheis G., Hilger N., McPhail M.J.W. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Exp Hepatol. 2018;8(3):301-313. https://dx.doi.org/10.1016/j.jceh.2018.05.00434.Wong C., Lee M.H., Yaow C.Y.L., et al. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Front Endocrinol. 2021;12:609110. https://dx.doi.org/10.3389/fendo.2021.60911035.Cusi K., Orsak B., Bril F., et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305-315. https://dx.doi.org/10.7326/M15-177436.Dongiovanni P., Petta S., Mannisto V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63(3):705-712. https://dx.doi.org/10.1016/j.jhep.2015.05.00637.Jarvis H., O’Keefe H., Craig D., et al. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open. 2022;12(1):e049767. https://dx.doi.org/10.1136/bmjopen-2021-04976738.Mato J.M., Cámara J., Paz J.F.D., et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30(6):1081-1089. https://dx.doi.org/10.1016/S0168-8278(99)80263-3